Advancing Small Molecule Program from Hit to Candidate - Webinar by Jubilant Biosys

Case Study: Small molecule inhibitors of NMMT for treatment of metabolic disorders

The small molecule program was started with the aim to identify lead series and lead compounds for the inhibition of NNMT to treat metabolic disorders.

The project team faced numerous challenges during the program such as moderate ADME profile of the starting compounds, establishing biochemical assays for the target, and several selectivity assays, establishing target engagement and efficacy models and such. In this webinar, we will be discussing the strategic workflows to overcome such challenges, our project journey and swift successful delivery of a lead series and lead compounds.

Our 4D focused project approach, attributed premier importance to scientific value addition, driving scientific insights about the metabolic therapeutic domain – pharmacological benefits in vivo. In addition, we offer a platform for all the attendants to share their best practices, experiences, and bring in their queries.

Webinar Takeaways:

• Overcoming Hit to Lead challenges
• Deciding on the best approach
• Fast-tracking Milestone achievement

Webinar Date: Tuesday, 8th December 2020, 11:00am EST / 8:00am PST

Speaker:

Dr. Takeshi Yura

Vice President – Medicinal Chemistry

Dr. Yura has more than 28 years’ experience in Medicinal and Organic Chemistry, beginning his career with Tanabe Seiyaku Tokyo Research Center where he worked as Research Chemist. Post this he was associated with Ciba Geigy Japan (Takarazuka Research Center), Bayer Yakuhin (Research Center Kyoto), Pfizer Japan (Pfizer Global Research and Development Nagoya Laboratories) and Dishman Japan Ltd.

Before joining Jubilant Biosys, Dr. Yura worked with Albany Molecular Research Singapore Research Centre, Pte. Ltd, as Vice President, Discovery and Development Services for Asia and General Manager for Singapore Research Centre. At AMRI he was responsible for, AMRI Singapore Research Centre’s chemistry and biology operations and AMRI Hyderabad Research Centre.

Dr. Yura was awarded a PhD degree in Chemistry from University of Tokyo, Japan. He has completed his Executive MBA program at Temple University, Tokyo, Japan.

About Jubilant Biosys Limited:

Jubilant Biosys is a leading contract research organization that offers contract research & development services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services such as Biology, DMPK, Toxicology as well as Medicinal Chemistry, PR&D and GMP scale-up capabilities up to phase II. It has a proven track record of delivering over 75 integrated programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases.

Biosys specializes in integrated drug discovery services, analytical chemistry services, synthetic chemistry services, and discovery informatics services for the global pharmaceutical industry. In order to be the preferred collaborator in the drug discovery domain, Jubilant Biosys is committed to complying with and continually improve its quality systems to provide the following services:

• Contract Research
• Pre-clinical CRO
• Drug Discovery
• Virtual Screening
• Protein Crystallization
• Toxicology & In-vitro ADME
• Medicinal Chemistry
• Synthetic & Developmental Chemistry
• Pharmacology

Jubilant Biosys at a Glance:

• A boutique CRO with a talented team of 700+ scientists
• New and adaptable technologies to accelerate drug discovery and improve decision-making quality
• A highly experienced scientific team that has delivered 75+ integrated discovery programs
• Continuous investment in the future of drug discovery and development through expansion
• Leadership with a global presence in the US, EU, and Japan

For more info, please visit: https://www.jubilantbiosys.com/advancing-small-molecule-program-from-hit-to-candidate/

I'm a digital marketing enthusiast that specializes in strategy and growth in the digital world, currently working with Dignitas Digital, a leading digital marketing agency in Delhi, India.